Michael Barbella, Managing Editor01.24.24
MedX Health Corp. has appointed Jeffrey Morris as vice president of Sales and Marketing.
"We are very pleased to have Jeffrey join our team," MedX Health CEO Stephen Lockyer said. "We searched for a recognized health-care executive in the diagnostics space, a leader with proven sales and marketing expertise, one who is results driven and up to the task of building a strong team at MedX. Jeffrey met all of those criteria, and we are glad to have him aboard. He will be a critical part of our success."
With more than 20 years of experience, Morris has worked for Pfizer Inc., Boehringer-Ingelheim Canada, Merck Canada Inc., Novartis Vaccines and Sanofi Pasteur. Morris brings a strong track record of establishing new territory clinic and physician relationships, implementing and leading large-scale sales and marketing teams and driving sales results.
"I am honored to be joining MedX Health at this pivotal stage of growth for the company," Morris stated. "With our unique teledermatology technology platform, I look forward to establishing MedX as an industry leader."
MedX’s telemedicine platform allows healthcare practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. Teledermatology, is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments.
Headquartered in Ontario, Canada, MedX Health Corp. is a medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include handheld devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey.
"We are very pleased to have Jeffrey join our team," MedX Health CEO Stephen Lockyer said. "We searched for a recognized health-care executive in the diagnostics space, a leader with proven sales and marketing expertise, one who is results driven and up to the task of building a strong team at MedX. Jeffrey met all of those criteria, and we are glad to have him aboard. He will be a critical part of our success."
With more than 20 years of experience, Morris has worked for Pfizer Inc., Boehringer-Ingelheim Canada, Merck Canada Inc., Novartis Vaccines and Sanofi Pasteur. Morris brings a strong track record of establishing new territory clinic and physician relationships, implementing and leading large-scale sales and marketing teams and driving sales results.
"I am honored to be joining MedX Health at this pivotal stage of growth for the company," Morris stated. "With our unique teledermatology technology platform, I look forward to establishing MedX as an industry leader."
MedX’s telemedicine platform allows healthcare practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. Teledermatology, is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments.
Headquartered in Ontario, Canada, MedX Health Corp. is a medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include handheld devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey.